Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
09885 藥師幫
YSB
Listing Date2023/06/28
Listing Price20.000
 
Quote
  • 7.610 -0.200 (-2.561%)    Sink Below Listing Price
  • 15-min delayed, last update: 27/05/2024 17:59
Subscription Result
  • Subscription Rate
    5.60x
  • Guarantee One Lot Size
    6 lot
  • One Lot Success Rate
    30.01%
COMPANY PROFILE

YSB Inc. is a digital pharmaceutical platform serving businesses outside of hospitals in China. It recorded a GMV of RMB37.8 billion in 2022, representing a market share of 21% in China’s digital market of outside-of-hospital pharmaceutical circulation services.

--

The Group serves the largest digital pharmaceutical transaction and service network, including, among others, around 354,000 downstream pharmacies and around 173,000 primary healthcare institutions, as of 31 December 2022. Furthermore, it had 308,000 average number of monthly active buyers (“MAB”) in 2022, the highest among digital pharmaceutical platforms serving businesses outside of hospitals in China. The average number of monthly available stock keeping units (SKUs) transacted on its platform was around 3.3 million in 2022.

--

It strategically designed mapping strategy for its own warehousing networking and had built 20 smart warehouses in 19 cities as of 31 December 2022.

BASIC INFORMATION
MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot200
GLOBAL OFFERING
No. of Offer Shares15.81M shares
No. of International Offer Shares14.23M shares
No. of HK Offer Shares1.58M shares
Offer Price$19.00 - $23.00
Stock Code9885
Sponsor(s)China International Capital Corporation Hong Kong Securities Limited
Underwriter(s)China International Capital Corporation Hong Kong Securities Limited, CMB International Capital Limited, ICBC International Securities Limited, ABCI Securities Company Limited, Fosun International Securities Limited, Futu Securities International (Hong Kong) Limited, Tiger Brokers (HK) Global Limited, Valuable Capital Limited, Patrons Securities Limited
TIME TABLE
Application PeriodJun 15 (Thu) - noon, Jun 20 (Tue)
Price Determination DateJun 20 (Tue)
Result Announcement DateOn or before Jun 27 (Tue)
Result Announcement DateOn or before Jun 27 (Tue)
Result Announcement DateOn or before Jun 27 (Tue)
Dealings in Shares commence onJun 28, 2023. (Wed)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$19.00 - $23.00
Capitalization12.02B - 14.54B
NAV / share ($)$-32.91 - $-32.48 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 21.00, the net proceeds raised would be HKD 253.60M, of which
45% : Further developing pharmaceutical circulation business
25% : Further developing other businesses
22% : Research and development
8% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
:
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.